Download PDF
Semin Thromb Hemost 2017; 43(08): 886-892
DOI: 10.1055/s-0037-1602377
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Bleeding Complications and Management on anticoagulant therapy

Sam Schulman
1   Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Publication Date:
01 April 2017 (online)

    Permissions and Reprints

Abstract

Patients treated with anticoagulants have an unavoidable risk of bleeding complications. There are, for all oral anticoagulants, several potential options for management of major bleeding. The first action is to assess the causative role of the anticoagulant in the current bleeding. Supportive measures have been assessed in several post hoc analyses of the phase III pivotal trials with the non–vitamin K antagonist oral anticoagulants (NOACs). Those results will be reviewed here together with emerging data on the efficacy and safety of the specific antidotes idarucizumab (for dabigatran) and andexanet-α (for factor Xa inhibitors). Regular or activated prothrombin complex concentrates are also evaluated and might have a role as alternatives for management of NOAC-associated major bleeding if the “specific” antidote is not available. Once hemostasis has been achieved, it is imperative to assess the possibility and timing of resumption of anticoagulation, as these patients have an inherent prothrombotic state and a non-negligible proportion of patients will have thromboembolic complications during the first month after the hemorrhage. Many factors will have to be taken into account for this decision and unfortunately the guidelines in this respect are very weak if at all available. This review will hopefully provide some assistance in the management of major bleeding and posthemorrhage care.

Keywords

bleeding - reversal - resumption - warfarin - NOACs
 

  • References

  • 1 Gailani D, Bane CE, Gruber A. Factor XI and contact activation as targets for antithrombotic therapy. J Thromb Haemost 2015; 13 (08) 1383-1395
    CrossrefPubMedGoogle Scholar
  • 2 Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 2012; 126 (20) 2381-2391
    CrossrefPubMedGoogle Scholar
  • 3 Lopes LC, Spencer FA, Neumann I. , et al. Bleeding risk in atrial fibrillation patients taking vitamin K antagonists: systematic review and meta-analysis. Clin Pharmacol Ther 2013; 94 (03) 367-375
    CrossrefPubMedGoogle Scholar
  • 4 Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 2014; 124 (15) 2450-2458
    CrossrefPubMedGoogle Scholar
  • 5 Larsen TB, Skjøth F, Nielsen PB, Kjældgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2016; 353: i3189
    PubMedGoogle Scholar
  • 6 Caldeira D, Barra M, Pinto FJ, Ferreira JJ, Costa J. Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis. J Neurol 2015; 262 (03) 516-522
    CrossrefPubMedGoogle Scholar
  • 7 Caldeira D, Rodrigues FB, Barra M. , et al. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. Heart 2015; 101 (15) 1204-1211
    CrossrefPubMedGoogle Scholar
  • 8 Majeed A, Meijer K, Larrazabal R. , et al. Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate. Thromb Haemost 2014; 111 (02) 233-239
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology 2013; 145 (01) 105-112.e15
    CrossrefPubMedGoogle Scholar
  • 10 van Ryn J, Stangier J, Haertter S. , et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103 (06) 1116-1127
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Garcia D, Barrett YC, Ramacciotti E, Weitz JI. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost 2013; 11 (02) 245-252
    CrossrefPubMedGoogle Scholar
  • 12 Holbrook A, Schulman S, Witt DM. , et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e152S-e184S
    CrossrefPubMedGoogle Scholar
  • 13 Lee SB, Manno EM, Layton KF, Wijdicks EF. Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP. Neurology 2006; 67 (07) 1272-1274
    CrossrefPubMedGoogle Scholar
  • 14 Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997; 77 (03) 477-480
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Chai-Adisaksopha C, Hillis C, Siegal DM. , et al. Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. Thromb Haemost 2016; 116 (05) 879-890
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Steiner T, Poli S, Griebe M. , et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol 2016; 15 (06) 566-573
    CrossrefPubMedGoogle Scholar
  • 17 Majeed A, Hwang H-G, Connolly SJ. , et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 2013; 128 (21) 2325-2332
    CrossrefPubMedGoogle Scholar
  • 18 Schiele F, van Ryn J, Canada K. , et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013; 121 (18) 3554-3562
    CrossrefPubMedGoogle Scholar
  • 19 Glund S, Stangier J, Schmohl M. , et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 2015; 386 (9994): 680-690
    CrossrefPubMedGoogle Scholar
  • 20 Pollack Jr CV, Reilly PA, Eikelboom J. , et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373 (06) 511-520
    CrossrefPubMedGoogle Scholar
  • 21 Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108 (02) 217-224
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Dager WE, Gosselin RC, Roberts AJ. Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. Crit Care Med 2013; 41 (05) e42-e46
    CrossrefPubMedGoogle Scholar
  • 23 Dibu JR, Weimer JM, Ahrens C, Manno E, Frontera JA. The role of FEIBA in reversing novel oral anticoagulants in intracerebral hemorrhage. Neurocrit Care 2016; 24 (03) 413-419
    CrossrefPubMedGoogle Scholar
  • 24 Schulman S, Ritchie B, Goy JK, Nahirniak S, Almutawa M, Ghanny S. Activated prothrombin complex concentrate for dabigatran-associated bleeding. Br J Haematol 2014; 164 (02) 308-310
    CrossrefPubMedGoogle Scholar
  • 25 Wong H, Keeling D. Activated prothrombin complex concentrate for the prevention of dabigatran-associated bleeding. Br J Haematol 2014; 166 (01) 152-153
    CrossrefPubMedGoogle Scholar
  • 26 Schulman S, Ritchie B, Phanco S, Nahirniak S. , et al. Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: A prospective cohort study. Thromb Res 2017; 152 (01) 44-48
    CrossrefPubMedGoogle Scholar
  • 27 Woo JS, Kapadia N, Phanco SE, Lynch CA. Positive outcome after intentional overdose of dabigatran. J Med Toxicol 2013; 9 (02) 192-195
    CrossrefPubMedGoogle Scholar
  • 28 Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49 (04) 259-268
    CrossrefPubMedGoogle Scholar
  • 29 Khadzhynov D, Wagner F, Formella S. , et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost 2013; 109 (04) 596-605
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Chai-Adisaksopha C, Hillis C, Lim W, Boonyawat K, Moffat K, Crowther M. Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. J Thromb Haemost 2015; 13 (10) 1790-1798
    CrossrefPubMedGoogle Scholar
  • 31 Granger CB, Alexander JH, McMurray JJ. , et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
    CrossrefPubMedGoogle Scholar
  • 32 Hylek EM, Held C, Alexander JH. , et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol 2014; ;27; 63 (20) 2141-2147
    CrossrefPubMedGoogle Scholar
  • 33 Eerenberg ES, Middeldorp S, Levi M, Lensing AW, Büller HR. Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. J Thromb Haemost 2015; 13 (09) 1590-1596
    CrossrefPubMedGoogle Scholar
  • 34 Piccini JP, Garg J, Patel MR. , et al; ROCKET AF Investigators. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J 2014; 35 (28) 1873-1880
    CrossrefPubMedGoogle Scholar
  • 35 Giugliano RP, Ruff CT, Braunwald E. , et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22) 2093-2104
    CrossrefPubMedGoogle Scholar
  • 36 Lu G, DeGuzman FR, Hollenbach SJ. , et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19 (04) 446-451
    CrossrefPubMedGoogle Scholar
  • 37 Connolly SJ, Milling Jr TJ, Eikelboom JW. , et al; ANNEXA-4 Investigators. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016; 375 (12) 1131-1141
    CrossrefPubMedGoogle Scholar
  • 38 Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124 (14) 1573-1579
    CrossrefPubMedGoogle Scholar
  • 39 Cheung YW, Barco S, Hutten BA, Meijers JC, Middeldorp S, Coppens M. In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers. J Thromb Haemost 2015; 13 (10) 1799-1805
    CrossrefPubMedGoogle Scholar
  • 40 Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E. , et al. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood. PLoS One 2013; 8 (11) e78696
    CrossrefPubMedGoogle Scholar
  • 41 Grandhi R, Newman WC, Zhang X. , et al. Administration of 4-factor prothrombin complex concentrate as an antidote for intracranial bleeding in patients taking direct factor Xa inhibitors. World Neurosurg 2015; 84 (06) 1956-1961
    CrossrefPubMedGoogle Scholar
  • 42 Levi M, Moore KT, Castillejos CF. , et al. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost 2014; 12 (09) 1428-1436
    CrossrefPubMedGoogle Scholar
  • 43 Ansell JE, Bakhru SH, Laulicht BE. , et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 2014; 371 (22) 2141-2142
    CrossrefPubMedGoogle Scholar
  • 44 Lu G, Kotha J, Cardenas JM. , et al. In vitro characterization of andexanet alfa (PRT064445), a specific FXa inhibitor antidote versus aripazine (PER977), a non-specific reversal agent. Circulation 2014; 130: 18218 (Abstract)
    PubMedGoogle Scholar
  • 45 Pennlert J, Asplund K, Carlberg B. , et al. Antithrombotic treatment following intracerebral hemorrhage in patients with and without atrial fibrillation. Stroke 2015; 46 (08) 2094-2099
    CrossrefPubMedGoogle Scholar
  • 46 Paciaroni M, Agnelli G. Should oral anticoagulants be restarted after warfarin-associated cerebral haemorrhage in patients with atrial fibrillation?. Thromb Haemost 2014; 111 (01) 14-18
    Article in Thieme ConnectPubMedGoogle Scholar
  • 47 Schulman S. Resumption of oral anticoagulation after warfarin-associated intracerebral hemorrhage: no. Stroke 2011; 42 (12) 3663-3664
    CrossrefPubMedGoogle Scholar
  • 48 Flynn RW, MacDonald TM, Murray GD, Doney AS. Systematic review of observational research studying the long-term use of antithrombotic medicines following intracerebral hemorrhage. Cardiovasc Ther 2010; 28 (03) 177-184
    CrossrefPubMedGoogle Scholar
  • 49 Majeed A, Kim YK, Roberts RS, Holmström M, Schulman S. Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke 2010; 41 (12) 2860-2866
    CrossrefPubMedGoogle Scholar
  • 50 Eckman MH, Rosand J, Knudsen KA, Singer DE, Greenberg SM. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke 2003; 34 (07) 1710-1716
    CrossrefPubMedGoogle Scholar
  • 51 Pennlert J, Overholser R, Asplund K. , et al. Optimal timing of anticoagulant treatment following intracerebral hemorrhage in patients with atrial fibrillation. Stroke 2017; 48 (02) 314-320
    CrossrefPubMedGoogle Scholar
  • 52 Majeed A, Wallvik N, Eriksson J. , et al. Optimal timing of warfarin resumption after warfarin related upper gastrointestinal bleeding. A risk modeling analysis. Thromb Haemost 2016 Dec 22. DOI: 10.1160/TH16-07-0498.
    PubMedGoogle Scholar
  • 53 MacLean S, Mulla S, Akl EA. , et al. Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e1S-e23S
    CrossrefPubMedGoogle Scholar
  • 54 Witt DM, Delate T, Garcia DA. , et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med 2012; 172 (19) 1484-1491
    CrossrefPubMedGoogle Scholar
  • 55 Qureshi W, Mittal C, Patsias I. , et al. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am J Cardiol 2014; 113 (04) 662-668
    CrossrefPubMedGoogle Scholar
  • 56 Lansberg MG, O'Donnell MJ, Khatri P. , et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e601S-e636S
    CrossrefPubMedGoogle Scholar